Ductal Carcinoma In Situ

Area of Science:

• Oncology
• Breast Cancer Research
• Surgical Oncology

Background:

• Ductal carcinoma in situ (DCIS) incidence has remained stable for ten years.
• DCIS generally presents an excellent prognosis for patients.
• Breast conservation therapy is a safe and effective treatment option for the majority of DCIS patients.

Purpose of the Study:

• To review current management strategies for DCIS.
• To evaluate adjuvant therapies for reducing local recurrence.
• To explore future directions in DCIS treatment, including predictive tools and surgical omission.

Main Methods:

• Review of existing literature on DCIS management.
• Analysis of data regarding adjuvant whole breast radiation therapy and accelerated partial breast irradiation.
• Evaluation of the role and risks of adjuvant hormonal therapy.

Main Results:

• Adjuvant whole breast radiation therapy is recommended to lower local recurrence risk.
• Accelerated partial breast irradiation shows promise for reduced toxicity and improved cosmetic outcomes.
• Adjuvant hormonal therapy can decrease local recurrence but requires cautious application.

Conclusions:

• Current management emphasizes breast conservation with adjuvant radiation.
• Accelerated partial breast irradiation offers a potentially less toxic alternative.
• Future research should focus on predictive tools to guide adjuvant therapy and identify patients suitable for surgical omission.